Colorado is currently home to 1810 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06001788
Recruiting
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: Colorado Blood Cancer Institute, Denver, Colorado
Conditions: AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
Register for Updates
Study of Novel Treatment Combinations in Patients With Lung Cancer
NCT05633667
Recruiting
The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2025
Locations: Rocky Mountain Cancer Center,Substudy-01, Denver, Colorado
Conditions: Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
Register for Updates
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT05232916
Recruiting
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of care therapy. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart. A third o... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/11/2025
Locations: Rocky Mountain Cancer Centers, Denver, Colorado
Conditions: Breast Cancer
Register for Updates
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
NCT07075718
Recruiting
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Glaukos Investigative Site, Grand Junction, Colorado
Conditions: Glaucoma
Register for Updates
Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod
NCT06860633
Recruiting
This study plans to learn more about if the drug efgartigimod can be used in the hospital to treat exacerbations in participants with myasthenia gravis (MG). Efgartigimod has been approved by the FDA for ongoing (chronic) treatment of generalized MG in adult patients who are anti-acetylcholine receptor (AChR) antibody positive but has not been studied in the treatment of worsening weakness requiring hospital admission (known as "exacerbation"). This investigation aims to see if using efgartigimo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: University of Colorado, Aurora, Colorado
Conditions: Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis
Register for Updates
Maternal Fetal Device Performance Twins
NCT06835647
Recruiting
Maternal Fetal Monitoring devices assist the health care professional in acquiring, monitoring, and storing fetal and maternal physiologic data which support clinical decision making for pregnant women and assesses the overall fetal health status during pregnancy and delivery. This study aims to support a new maternal fetal monitoring device with clinical data by collecting simultaneous, continuous, external, distinguishable FHRs from twin pregnancies using ultrasound Doppler transducers from th... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Element Materials Technology, Louisville, Colorado
Conditions: Pregnancy
Register for Updates
Bionic Pancreas in CFRD
NCT06449677
Recruiting
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with cystic fibrosis-related diabetes (CFRD). After 13 weeks, participants will continue in a 13-week Extension Phase in which the BP group will continue to us... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
07/10/2025
Locations: University of Colorado-Barbara Davis Center for Diabetes, Aurora, Colorado
Conditions: Cystic Fibrosis-related Diabetes
Register for Updates
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
NCT06355531
Recruiting
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
07/10/2025
Locations: Rocky Mountain Movement Disorders Center, Denver, Colorado
Conditions: Progressive Supranuclear Palsy
Register for Updates
A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS
NCT06144645
Recruiting
The goal of the VNS4PWS clinical study is to test the efficacy, safety, and acceptability of transcutaneous vagus nerve stimulation (tVNS) treatment in people with PWS.
Gender:
ALL
Ages:
Between 10 years and 40 years
Trial Updated:
07/10/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Prader-Willi Syndrome
Register for Updates
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
NCT05382338
Recruiting
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back after treatment. Subjects with low-risk medulloblastoma typically have a lower chance of the cancer coming back than subjects with average-risk medulloblastoma. Although treatment for newly diagnosed average-risk and low-risk medulloblastoma is generally effect... Read More
Gender:
ALL
Ages:
Between 4 years and 21 years
Trial Updated:
07/10/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Childhood Medulloblastoma
Register for Updates
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)
NCT04375800
Recruiting
This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to \<12 years and weighing \<45 kg, who are treatment-naive (TN) or have been virologically suppressed (VS) on stable combination antiretroviral therapy (cART) for ≥3 months with no history of treatment failure. The first primary objective is to evaluate the steady state pharmacokinetics (PK) of doravirine (DOR) \[MK-1439\] when given in combinat... Read More
Gender:
ALL
Ages:
Between 4 weeks and 11 years
Trial Updated:
07/10/2025
Locations: University of Colorado at Denver ( Site 0108), Aurora, Colorado
Conditions: Human Immunodeficiency Virus (HIV) Infection
Register for Updates
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, ET (Essential Thrombocythemia)
Register for Updates